FLT3 and neoplasm: Additionally, the coadministration of A485 and quizartinib enhanced the inhibition of H3K27Ac and c-Myc expression, as well as FLT3 downstream signaling, including STAT5 and ERK phosphorylation, in tumor tissues from MV-4-11/quizartinib xenografts (Fig. 5l; Supplementary Fig. S5i).